Back
Edge
StocktwitsEarnings
Official STOCKTWITS Representative
symbol logo$CRMD Q1 '25 Earnings Results & Recap CorMedix reported Q1 2025 EPS of $0.30, exceeding the estimate of $0.26, and revenue of $39.1M, which is higher than the estimated $36.94M; however, Q2 revenue is expected to decline sequentially due to the timing of shipments to U.S. Renal Care, while long-term growth is expected with the potential for significant market expansion.
1
2

Since Post

Full Details

Advertisement|Remove ads.